Natalizumab every 7 weeks vs 4 weeks dosing: equivalent efficacy in 335 multiple sclerosis patients

Takahiko Saida

Presentation information

Oral Session

[O-46] Oral Session 46 Clinical trial and Regenerative medicine3

Sat. May 22, 2021 10:15 AM - 11:45 AM Room 10 (ICC Kyoto 1F Swan Hall)

Chair：Abe Koji(Department of Neurology, Okayama University)

[O-46-1] Natalizumab every 7 weeks vs 4 weeks dosing: equivalent efficacy in 335 multiple sclerosis patients

^○Takahiko Saida^1,2,4, Qi Hao^1,2,4, Michiko Yamauchi^1,4, Kyoko Saida^1,2,3,4 (1.Kansai Multiple Sclerosis Center, Japan, 2.Irino Clinic, Japan, 3.Kyoto-Hakuaikai Hospital, Dept. of Neurology, 4.Institute of Multiple Sclerosis Therapeutics, Japan)

Abstract password authentication.
Password is written on a pocket program and name badge.